Sophiris Bio Closes $65 Million Public Offering

SAN DIEGO and VANCOUVER, Aug. 23, 2013 -- (Healthcare Sales & Marketing Network) - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing a clinical-stage, targeted treatment fo... Biopharmaceuticals, Urology, Venture CapitalSophiris Bio, benign prostatic hyperplasia, PRX302
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news